


## Hemoperfusion, Advanced Technology

Hemoperfusion is a blood purification method based on hemoadsorption technology. Jafron HA hemoperfusion cartridges contain brown beads made from **neutral macro-porous resin**. Under the electron microscopy, it shows the 3D network structure working as the **molecule sieve** aimed at adsorbing endogenous and exogenous molecules including inflammatory mediators and cytokines, bilirubin, metabolic toxins, protein-bound toxins and residual drugs. Hemoperfusion therapies are commonly applied in ESRD, acute poisoning, critical disease, hepatopathy, immune disease, etc.



Jafron HA hemoperfusion cartridges have advantages of

- High mechanical strength of adsorbents
- Large adsorptive surface area
- Porosity control technology
- Good biocompatibility<sup>[1-2]</sup>  
Advanced coating technology & optimized hemodynamics

\*Contraindications, Warnings and Precautions refer to Instructions For Use.

## JAFRON - Global manufacturer and supplier of adsorption columns



Jafron Headquarters



CE



ISO 9001



EN ISO 13485



### JAFRON BIOMEDICAL CO., LTD.

Address: No. 98, Technology Sixth Road, High-tech Zone, Zhuhai City, 519085, Guangdong, China.  
Tel: +86 (756) 3689708  
E-mail: [overseatrade@jafron.com](mailto:overseatrade@jafron.com)  
Website: [en.jafron.com](http://en.jafron.com)

(For Internal Use)



Stock Abbreviation: JFSW  
Stock Code: 300529



CY-CHANPINZONGHE-01-10-2021-EN



20 years in blood purification clinical practices

Widely used in more than 80 countries

More than 5 million treatments per year

Jafron Biomedical Co.,Ltd.


# Portfolio

| Model  | Clinical Benefits   | Therapies in Clinical Practice <sup>△</sup>   | Therapy Operation Modality*              |
|--|---|---|--|
| <b>HA130</b><br>        | Adsorb middle and protein-bound uremic toxins (e.g. PTH, leptin, β <sub>2</sub> -MG etc.) | <b>ESRD</b> <ul style="list-style-type: none"> <li>• Skin Itching</li> <li>• Renal Osteodystrophy</li> <li>• Cardiovascular Disease</li> <li>• Refractory Hypertension</li> <li>• Microinflammatory state</li> <li>• Malnutrition</li> <li>• Insomnia</li> </ul>  | (2)                                      |
| <b>HA230</b><br>        | Remove overdose drugs and poisons   | <b>Acute Poisoning</b> <ul style="list-style-type: none"> <li>• Drug Overdose: Barbitone, Digoxin, etc.</li> <li>• Biotoxin: Snake/Bee Venom, etc.</li> <li>• Pesticides: AOPP, PQ, etc.</li> <li>• Rodenticides</li> <li>• Industrial Poisoning: Zinc Sulphate, etc.</li> <li>• Chemotherapy--Cytostatics</li> </ul> | (1)(2)                                   |
| <b>HA330/HA380</b><br> | Remove inflammatory mediators and cytokines   | <b>Critical Disease</b> <ul style="list-style-type: none"> <li>• Cardiopulmonary Bypass</li> <li>• Sepsis, Septic Shock</li> <li>• Acute Pancreatitis</li> <li>• Coronavirus Pneumonia</li> <li>• Leptospirosis</li> <li>• Dengue</li> <li>• Severe Burn</li> <li>• MODS</li> <li>• ARDS</li> </ul>                   | (1)(2)(3)                                |
| <b>HA330-II</b><br>   | Broad-spectrum adsorb toxins such as inflammatory mediators, etc.                         | <b>Liver Disease</b> <ul style="list-style-type: none"> <li>• Hepatic Encephalopathy</li> <li>• Drug-induced Liver Damage (DIDL)</li> </ul>   | (1) (2) (5)                              |
| <b>BS330</b><br>      | Absorb bilirubin and bile acid  | <b>Liver Disease</b> <ul style="list-style-type: none"> <li>• Hyperbilirubinemia</li> <li>• Hyperbileacidemia</li> </ul>  | (4)(5)<br>Support plasma adsorption only |
| <b>DPMAS</b><br>      | Remove bilirubin and bile acid while clearing inflammatory mediators                      | <b>Liver Disease</b> <ul style="list-style-type: none"> <li>• Liver Transplant</li> <li>• Hepatitis</li> <li>• Liver Failure</li> </ul>   | (5)<br>Support plasma adsorption only    |
| <b>HA280</b><br>      | Remove immune substances and inflammatory mediators                                       | <b>Immune Disease</b> <ul style="list-style-type: none"> <li>• Rheumatoid Arthritis</li> <li>• Sensitive Purpura</li> <li>• Psoriasis</li> <li>• Pemphigus</li> <li>• Severe Drug Eruption</li> </ul>   | (1) (2)                                  |
| <b>DNA230</b><br>     | Remove ANA, anti-ds-DNA antibodies, and immunologic complexes                             | <b>Immune Disease</b> <ul style="list-style-type: none"> <li>• Systemic Lupus Erythematosus (SLE) and its complications</li> </ul>  | (1) (2) (4)                              |


<sup>△</sup>According to clinical practices, the cartridge has been used in the listed conditions. Detailed information please visit en.jafron.com.  
 \*Please refer to the next page for operation modality demonstration.

## Operation Modality


(1) Hemoperfusion (HP)




(2) HP+HD/CRRT




(3) HP+CPB/ECMO




(4) Plasma Adsorption (PA)



(5) Double Plasma Molecular Adsorption System (DPMAS)



## Hybrid Therapies



\*Hybrid therapies are recommended according to patient's condition.<sup>[3]</sup>

### References

[1] Pomarè Montin, D. et al. Biocompatibility and Cytotoxic Evaluation of New Sorbent Cartridges for Blood Hemoperfusion. Blood Purification 2018; 46, 187-195.  
 [2] Ankawi, G. et al. A New Series of Sorbent Devices for Multiple Clinical Purposes: Current Evidence and Future Directions. Blood Purification 2019; 47, 94-100.  
 [3] Ronco, C. et al. Coronavirus epidemic: preparing for extracorporeal organ support in intensive care. published online Feb 21. The Lancet Respiratory Medicine 8, e26 (2020).